沙利文发布《中国猫犬驱虫药行业发展白皮书》
Frost & Sullivan Releases the " White Paper on the Veterinary Antiparasitic Market for Cats and Dogs in China "
中国宠物经济正经历从高速扩张向高质量深耕的关键跃迁，2025年其市场规模已强势突破3,000亿元大关。宠物猫犬数量的持续增长，宠物医疗及驱虫药市场正迈入存量博弈全面深化的新竞争周期。报告指出，中国猫犬驱虫药出厂规模在2025年已达26.3亿元，其中内外同驱驱虫药产品凭借便捷与广谱优势占据最大市场份额。
国内猫犬驱虫药市场长期由外资企业主导，以硕腾为代表的跨国动保巨头凭借强大的原研创新能力、完整的产品结构以及严苛的品质壁垒，广受消费者欢迎，占据行业第一梯队。其中，硕腾旗下的大宠爱品牌也凭借其温和有效的产品特色，与宠主建立深厚的客户信任，是这一梯队的代表成员。中国猫犬驱虫药行业整体的市场集中度较高，按2023至2025年整体的规模计，市场CR3达46.3%。
展望未来，随着科学养宠、安全用药意识深度普及，单纯的低价药将难以为继。头部企业需将竞争战略升维，通过深化专业渠道绑定、定制全生命周期管理方案及推进覆盖研发、生产到市场适配的本土化品控体系，赋能驱虫药行业的可持续健康发展。
China's pet economy is transitioning from rapid expansion to high-quality growth, with its market size exceeding RMB 300 billion in 2025. The rising feline and canine population is steering the veterinary and antiparasitic drug market toward a phase of concurrent volume growth amid intensifying stock-market competition. In 2025, the factory-gate value of canine and feline antiparasitic drugs in China reached RMB 2.63 billion, with combination endo-ectoparasitic products holding the largest share due to their broad-spectrum efficacy and ease of use.
Regarding the competitive landscape, three multinational animal health companies—Zoetis, Boehringer Ingelheim, and Elanco, collectively captured nearly half of the market sales, backed by strong R&D capabilities, comprehensive product lines, and rigorous quality standards. Zoetis's Revolution ranked first in both the overall and feline-specific antiparasitic segments.
Looking forward, as awareness of science-based pet care and medication safety grows, low-price products will face increasing challenges. Leading companies are expected to upgrade their strategies by strengthening professional channel partnerships, developing lifecycle management solutions, and advancing localized quality innovation to support the industry's sustainable growth.
点击以下链接，查看节选版报告：
如果您对中国猫犬驱虫药市场有进一步的研究需求，请联系我们：
沙利文 楼先生
E-mail: alan.lou@frostchina.com
